// App-Quantinova.ai

SAT0275 : MAINTAINED BENEFIT IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE TAPERING: RESULTS FROM THE OPEN-LABEL, LONG-TERM EXTENSION OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL

Researchers

Presenter

  • J. H. Stone

Principal Investigators

  • J. Han

  • S. Unizony

  • M. Aringer

  • D. Blockmans

  • E. Brouwer

  • M. C. Cid

  • B. Dasgupta

  • J. Rech

  • C. Salvarani

  • R. Spiera

  • M. Bao

Medical Centers

  • Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

  • Genentech, Inc., South San Francisco, California, United States of America

  • Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany

  • General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium

  • Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

  • Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut -Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain

  • Southend University Hospital NHS Trut, Westcliff on Sea, United Kingdom

  • Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany

  • Division of Oncology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy

  • Hosp Special Surg, Cornell, United States of America

Locations

  • United States

  • Germany

  • Belgium

  • Netherlands

  • Spain

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Autoimmune (AI)

Disease

  • Giant cell arteritis

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Roche Holding AG

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved